Compare AX & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AX | IMVT |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.2B |
| IPO Year | 2005 | N/A |
| Metric | AX | IMVT |
|---|---|---|
| Price | $82.19 | $22.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $96.86 | $27.71 |
| AVG Volume (30 Days) | 266.1K | ★ 1.3M |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.44 | N/A |
| Revenue | ★ $1,202,571,000.00 | N/A |
| Revenue This Year | $17.36 | N/A |
| Revenue Next Year | $10.34 | N/A |
| P/E Ratio | $11.06 | ★ N/A |
| Revenue Growth | ★ 6.69 | N/A |
| 52 Week Low | $54.46 | $12.72 |
| 52 Week High | $93.84 | $29.49 |
| Indicator | AX | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 47.69 |
| Support Level | $81.48 | $21.86 |
| Resistance Level | $83.43 | $24.42 |
| Average True Range (ATR) | 2.29 | 1.19 |
| MACD | 0.59 | -0.33 |
| Stochastic Oscillator | 83.01 | 7.07 |
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment. The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.